| [1］ Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study［J］. Hum Reprod,2013 Jun 27.［Epub ahead of print］ [2］ Azziz R,Woods KS，Reyna R，et al.The prevalence and features of the polycystic ovary syndrome role in an unselected population［J］．J Clin Endocrinol Metab，2004，89:2745-2749. [3］ Fruzzetti F，Bersi C，Parrini D，et al. Effect of long-term naltrexone treatment on endocrine，profile，clinical features，and insulin sensitivity in obese women with polycystic ovary syndrome［J］.Fertil Steril，2002，77(5)：936-944. [4］ Romualdi D，Guido M，Calmpelli M，et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo and hyperinsulinaemic obese patients with polycystic ovary syndrome［J］.Hum Peprod，2003，18(6)：1210-1218. [5］ Baranowska B，Radzikowska M，Wasilewska DE，et al. Neuropeptide Y，leptin，galanin and insulin in women with polycystic ovary syndrome［J］.Gynecol Endocrinol，1999，13(5)：344-351. [6］ La Marca A，Morgante G，Palumbo M，et al.Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating normone in women with polycystic ovary syndrome［J］.Fertil Steril，2002，78(6)：1234-1239. [7］ Chakraborty P, Goswami SK, Rajani S, et al. Recurrent pregnancy loss in polycystic ovary syndrome: role of hyperhomocysteinemia and insulin resistance［J］. PLoS One,2013, 8(5):e64446. doi: 10.1371. [8］ Abbott DH, Bacha F. Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood［J］. Fertil Steril, 2013,100(1):2-11. [9］ Ciotta L，De Leo V，Farina M，et al.Endiocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia［J］.Gynecol Obstet Invest，2001，51(1)：44-50. [10］ De Leo V，Musacchio MC，Morgante G，et al. Metformin treatment is effective in obese teenage girl with PCOS［J］．Hum Reprod，2006，21(9)：2252-2256． [11］ Eisenhart S，Schwarzmann N.Early effects of metformin in woman with polycystic ovary syndrome:a prospective randomized，double-blind，placebo-controlled trial［J］．J Clin Endocrinol Metab，2006，91(4)：946-952． [12］ Bozdag G, Yildiz BO.Interventions for the metabolic dysfunction in polycystic ovary syndrome［J］. Steroids, 2013,78(8):777-781. [13］ Du Q, Yang S, Wang YJ,et al. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials［J］. Adv Ther,2012,29(9):763-774. [14］ Garmes HM，Tambascia MA, Zantut-Wittmann DE. Endocrinometabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome［J］.Gynecol Endocrinol， 2005，21(6):317-323. [15］ Rautio KT， Katrina MP，Laure CT， et al. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome:a randomized placebo-controlled study［J］. Fertil Steril， 2007，87(1):202-226. [16］ Liao L, Tian YJ, Zhao JJ,et al. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome［J］. Chin Med J (Engl),2011 ,124(5):714-718. |
